The good news is that the team at UBS don’t believe that Vyvgart will have an overly large impact on CSL’s revenue. It sees the worst-case scenario as a ~3% revenue hit. Though, even then, the broker feels that is unlikely.As a result, it may be unnecessary to worry too much about this news. And with UBS retaining its buy rating and $340.00 price target, it could prove to be an opportune time to pick up CSL shares while they are cheap.
UBS - CSL no need to worry about Argenx
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$285.29 |
Change
1.900(0.67%) |
Mkt cap ! $138.1B | |||
| Open | High | Low | Value | Volume |
| $286.24 | $286.95 | $283.70 | $138.5M | 483.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 79 | $285.29 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $285.40 | 112 | 2 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| CSL (ASX) Chart |